Who
Ryan Bond
Director
Company insider
Files Form 4 as: Chief Strategy Officer, Aclarion.
In numbers
- Trades disclosed
- 6
- Buys
- 2
- Sells
- 0
- Bought
- $156K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 22 Apr 2022
- Last trade
- 13 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 17 Aug 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $50K21,122 at $2.37 | filing |
| 13 Aug 2026filed 17 Aug 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $50K21,122 at $2.37 | filing |
| 11 Jun 2026filed 12 Jun 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 22 Apr 2022filed 25 Apr 2022 | ACON Aclarionoption or derivative · Diagnostics & Labs | SEC FORM 4 Code P | $15K21,000 at $0.73 | filing |
| 22 Apr 2022filed 25 Apr 2022 | ACON AclarionDiagnostics & Labs | SEC FORM 4 Bought | $56K20,000 at $2.80 | filing |
News
Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar DiscsACON · manilatimes.net · 22 Oct 2026Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026ACON · manilatimes.net · 20 Oct 2026
0 headlines in the last 90 days name Ryan Bond; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.